1
|
Shen J, Liu J. Bruton's tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review. Front Oncol 2022; 12:1034668. [PMID: 36465385 PMCID: PMC9713408 DOI: 10.3389/fonc.2022.1034668] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2022] [Accepted: 10/31/2022] [Indexed: 09/19/2023] Open
Abstract
Primary central nervous system lymphoma (PCNSL) is a highly aggressive brain tumor with poor prognosis if no treatment. The activation of the NF-κB (nuclear factor kappa-B) is the oncogenic hallmark of PCNSL, and it was driven by B cell receptor (BCR) and Toll-like receptor (TLR) signaling pathways. The emergence of Bruton's tyrosine kinase inhibitors (BTKis) has brought the dawn of life to patients with PCNSL. This review summarizes the management of PCNSL with BTKis and potential molecular mechanisms of BTKi in the treatment of PCNSL. And the review will focus on the clinical applications of BTKi in the treatment of PCNSL including the efficacy and adverse events, the clinical trials currently being carried out, the underlying mechanisms of resistance to BTKi and possible solutions to drug resistance.
Collapse
Affiliation(s)
- Jing Shen
- Department of Hematology, Capital Medical University Affiliated Beijing Friendship Hospital, Beijing, China
| | - Jinghua Liu
- Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China
- Department of Hematology, Northern Theater General Hospital, Shenyang, China
| |
Collapse
|
2
|
Wang C, Guan W, Chen R, Levi-Kalisman Y, Xu Y, Zhang L, Zhou M, Xu G, Dou H. Fluorescent glycan nanoparticle-based FACS assays for the identification of genuine drug-resistant cancer cells with differentiation potential. NANO RESEARCH 2020; 13:3110-3122. [DOI: 10.1007/s12274-020-2981-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/08/2020] [Revised: 07/09/2020] [Accepted: 07/10/2020] [Indexed: 08/29/2023]
|
3
|
George B, Mullick Chowdhury S, Hart A, Sircar A, Singh SK, Nath UK, Mamgain M, Singhal NK, Sehgal L, Jain N. Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell lymphomas. Cancers (Basel) 2020; 12:cancers12051328. [PMID: 32455989 PMCID: PMC7281539 DOI: 10.3390/cancers12051328] [Citation(s) in RCA: 54] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Revised: 05/17/2020] [Accepted: 05/19/2020] [Indexed: 02/03/2023] Open
Abstract
Chronic activation of B-cell receptor (BCR) signaling via Bruton tyrosine kinase (BTK) is largely considered to be one of the primary mechanisms driving disease progression in B-Cell lymphomas. Although the BTK-targeting agent ibrutinib has shown promising clinical responses, the presence of primary or acquired resistance is common and often leads to dismal clinical outcomes. Resistance to ibrutinib therapy can be mediated through genetic mutations, up-regulation of alternative survival pathways, or other unknown factors that are not targeted by ibrutinib therapy. Understanding the key determinants, including tumor heterogeneity and rewiring of the molecular networks during disease progression and therapy, will assist exploration of alternative therapeutic strategies. Towards the goal of overcoming ibrutinib resistance, multiple alternative therapeutic agents, including second- and third-generation BTK inhibitors and immunomodulatory drugs, have been discovered and tested in both pre-clinical and clinical settings. Although these agents have shown high response rates alone or in combination with ibrutinib in ibrutinib-treated relapsed/refractory(R/R) lymphoma patients, overall clinical outcomes have not been satisfactory due to drug-associated toxicities and incomplete remission. In this review, we discuss the mechanisms of ibrutinib resistance development in B-cell lymphoma including complexities associated with genomic alterations, non-genetic acquired resistance, cancer stem cells, and the tumor microenvironment. Furthermore, we focus our discussion on more comprehensive views of recent developments in therapeutic strategies to overcome ibrutinib resistance, including novel BTK inhibitors, clinical therapeutic agents, proteolysis-targeting chimeras and immunotherapy regimens.
Collapse
Affiliation(s)
- Bhawana George
- Department of Hematopathology, MD Anderson Cancer Center, Houston, TX 77030, USA;
| | - Sayan Mullick Chowdhury
- Department of Internal Medicine, the Ohio State University, Columbus, OH 43210, USA; (S.M.C.); (A.H.); (A.S.); (S.K.S.)
| | - Amber Hart
- Department of Internal Medicine, the Ohio State University, Columbus, OH 43210, USA; (S.M.C.); (A.H.); (A.S.); (S.K.S.)
| | - Anuvrat Sircar
- Department of Internal Medicine, the Ohio State University, Columbus, OH 43210, USA; (S.M.C.); (A.H.); (A.S.); (S.K.S.)
| | - Satish Kumar Singh
- Department of Internal Medicine, the Ohio State University, Columbus, OH 43210, USA; (S.M.C.); (A.H.); (A.S.); (S.K.S.)
| | - Uttam Kumar Nath
- Department of Medical Oncology & Hematology, All India Institute of Medical Sciences, Rishikesh 249203, India;
| | - Mukesh Mamgain
- Department of Biochemistry, All India Institute of Medical Sciences, Rishikesh 249203, India; (M.M.); (N.K.S.)
| | - Naveen Kumar Singhal
- Department of Biochemistry, All India Institute of Medical Sciences, Rishikesh 249203, India; (M.M.); (N.K.S.)
| | - Lalit Sehgal
- Department of Internal Medicine, the Ohio State University, Columbus, OH 43210, USA; (S.M.C.); (A.H.); (A.S.); (S.K.S.)
- Correspondence: (L.S.); (N.J.)
| | - Neeraj Jain
- Department of Medical Oncology & Hematology, All India Institute of Medical Sciences, Rishikesh 249203, India;
- Correspondence: (L.S.); (N.J.)
| |
Collapse
|
4
|
Song S, Li Y, Zhang K, Zhang X, Huang Y, Xu M, Li S, Guan X, Yang T, Liu Z, Jiang J, Luo Y, Lan Y. Cancer Stem Cells of Diffuse Large B Cell Lymphoma Are Not Enriched in the CD45 +CD19 - cells but in the ALDH high Cells. J Cancer 2020; 11:142-152. [PMID: 31892981 PMCID: PMC6930399 DOI: 10.7150/jca.35000] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2019] [Accepted: 09/12/2019] [Indexed: 02/07/2023] Open
Abstract
Although the existence of cancer stem cells (CSCs) has been suggested in diffuse large B cell lymphoma (DLBCL), there is still no definitive marker. CD45+CD19- has been regarded as a potential marker of CSCs in mantle cell lymphoma (MCL). So, we explored the role of CD45+CD19- in DLBCL. However, both CD45+CD19- cells and CD45+CD19+ cells did not generate tumors until more than 100,000 cells were inoculated in NOD/SCID mice, even CD45+CD19+ cells generated more and larger tumors, as well as the soft agar colony formation in vitro; The aldehyde dehydrogenase (ALDH) activity was also identified in this study. Only 1,500 ALDHhigh cells were enough to generate tumors in mice while the same number of ALDH- cells were not. Moreover, both groups formed tumors when more cells were inoculated, but ALDHhigh cells formed more and larger tumors. The similar result was obtained in vitro clonogenicity experiments. OCT4, SOX2, Nanog, and ABCG2 genes did not show any difference in CD45+CD19+, CD45+CD19-, ALDHhigh and ALDH- cells. Taken together, CSCs are not enriched in the CD45+CD19- cells but in the ALDHhigh cells in DLBCL cell lines.
Collapse
Affiliation(s)
- Shupeng Song
- Department of Infectious Disease, The First Affiliated Hospital of Harbin Medical University, Harbin, 150000, Hei Longjiang, China
| | - Yongguo Li
- Department of Infectious Disease, The First Affiliated Hospital of Harbin Medical University, Harbin, 150000, Hei Longjiang, China
| | - Kaili Zhang
- Department of Infectious Disease, The First Affiliated Hospital of Harbin Medical University, Harbin, 150000, Hei Longjiang, China
| | - Xi Zhang
- Department of Infectious Disease, The First Affiliated Hospital of Harbin Medical University, Harbin, 150000, Hei Longjiang, China
| | - Yanxin Huang
- Department of Infectious Disease, The First Affiliated Hospital of Harbin Medical University, Harbin, 150000, Hei Longjiang, China
| | - Mingyan Xu
- Department of Infectious Disease, The First Affiliated Hospital of Harbin Medical University, Harbin, 150000, Hei Longjiang, China
| | - Shuangxing Li
- Department of Infectious Disease, The First Affiliated Hospital of Harbin Medical University, Harbin, 150000, Hei Longjiang, China
| | - Xue Guan
- Animal experimental center, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150000, Hei Longjiang, China
| | - Tao Yang
- Instrument Center, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, 150000, Hei Longjiang, China
| | - Zhiyu Liu
- Central Laboratory, The First Affiliated Hospital of Harbin Medical University, Harbin, 150000, Hei Longjiang, China
| | - Jie Jiang
- Department of Pathology, The First Affiliated Hospital of Harbin Medical University, Harbin, 150000, Hei Longjiang, China
| | - Yunping Luo
- Department of Immunology, Institute of Basic Medical Science, Chinese Academy of Medical Science and Peking Union Medical College, Beijing,10005, China
| | - Yinghua Lan
- Department of Infectious Disease, The First Affiliated Hospital of Harbin Medical University, Harbin, 150000, Hei Longjiang, China
| |
Collapse
|
5
|
Ryu KJ, Park C, Hong M, Ko YH, Kim WS, Kim SJ. FOXO4 expression is related to stem cell-like properties and resistance to treatment in diffuse large B-cell lymphoma. Oncotarget 2018; 8:2466-2476. [PMID: 27911272 PMCID: PMC5356816 DOI: 10.18632/oncotarget.13690] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2016] [Accepted: 11/22/2016] [Indexed: 11/25/2022] Open
Abstract
Cancer stem cells are proposed to be responsible for resistance to chemotherapeutic agents, including doxorubicin. As phenylbutyrate enhances cancer stem cell properties, we analyzed surviving lymphoma cells after treatment with doxorubicin and phenylbutyrate. Human B-cell lymphoma cell lines, including Toledo, BJAB, Daudi, and Raji were incubated with IC90 concentrations of doxorubicin (300 nM) or phenylbutyrate (8 mM). After 48 h, live cells were sorted and analyzed for their resistance to treatment by examining gene expression profiles using cDNA microarray and biological characteristics. A small fraction of lymphoma cells that survived after drug application showed higher expression of stem cell markers (NANOG, andSOX2) and superior ability of self-renewal and sphere formation, compared to untreated control cells (P < 0.05). Gene expression analysis disclosed elevated expression of 41 genes, including FOXO4, in the four lymphoma cell lines that survived drug treatment. Overexpression of FOXO4 was evident in lymphoma cells surviving after phenylbutyrate treatment and refractory patient-derived lymphoma cells. Induction of FOXO4 expression promoted self-renewal whereas its knockdown led to diminished expression of stem cell markers and colony-forming ability of lymphoma cells. Immunohistochemical staining for FOXO4 in tumor tissue of diffuse large B-cell lymphoma revealed nuclear localization and significant association with poor prognosis. In conclusion, lymphoma cells resistant to treatment exhibit stem cell-like properties and enhanced FOXO4 expression. The presence of FOXO4-expressing cells in tumor tissue and their association with poor survival supports a role of FOXO4 in promoting stem cell properties resulting in poor outcomes.
Collapse
Affiliation(s)
- Kyung Ju Ryu
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea
| | - Chaehwa Park
- Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, Korea
| | - Mineui Hong
- Department of Pathology, Kangnam Sacred Heart Hospital, Hallym University Medical Center, Seoul, Korea
| | - Young Hyeh Ko
- Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Won Seog Kim
- Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Seok Jin Kim
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea.,Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| |
Collapse
|
6
|
Hu J, Li J, Yue X, Wang J, Liu J, Sun L, Kong D. Expression of the cancer stem cell markers ABCG2 and OCT-4 in right-sided colon cancer predicts recurrence and poor outcomes. Oncotarget 2017; 8:28463-28470. [PMID: 28212529 PMCID: PMC5438664 DOI: 10.18632/oncotarget.15307] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2016] [Accepted: 01/16/2017] [Indexed: 12/11/2022] Open
Abstract
Right-sided colon cancer (RCC) has a poorer prognosis and a higher relapse rate than left-sided colon cancer (LCC). Like cancer stem cells (CSCs), RCC cells cannot be fully eradicated and are often involved in relapse or metastasis. Because CSCs may be linked with poor outcomes, CSC markers may have prognostic value in RCC. ATP-binding cassette sub-family G member 2 (ABCG2) and OCT-4 (also known as POU5F1) are among the most useful markers for CSC identification. We therefore examined the malignant behavior of ABCG2 and OCT-4 in vitro and in vivo, and their expression was assessed in pathology tissues obtained from clinicopathologically recurrent and non-recurrent cases. Our survey suggested associations between ABCG2 and OCT-4 expression and RCC clinicopathological variables. No correlations were detected between ABCG2 or OCT-4 expression and age, gender, tumor size, or tumor shape, but ABCG2 expression correlated with TNM stage, tumor differentiation, and lymphovascular invasion. Additionally, expression of both ABCG2 and OCT-4 correlated with RCC recurrence and poor outcomes.
Collapse
Affiliation(s)
- Jun Hu
- Department of Colorectal Cancer Surgery, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China
| | - Jian Li
- Department of Lymphoma, State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, P.R. China
| | - Xin Yue
- Department of Colorectal Cancer Surgery, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China
| | - Jiacang Wang
- Department of Colorectal Cancer Surgery, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China
| | - Jianzhong Liu
- Department of Colorectal Cancer Surgery, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China
| | - Lin Sun
- Department of Pathology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China
| | - Dalu Kong
- Department of Colorectal Cancer Surgery, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China
| |
Collapse
|
7
|
Kim SM, Lee ST, Ryu KJ, Kim HJ, Kim SH, Ko YH, Kim WS, Kim SJ. A subset of CD45+/CD19 - cells in bone marrow may be associated with clinical outcomes of patients with mantle cell lymphoma. Leuk Lymphoma 2015; 56:3052-7. [PMID: 25739938 DOI: 10.3109/10428194.2015.1025391] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Mantle cell lymphoma has features of both indolent and aggressive non-Hodgkin lymphomas. Repeated relapses leading to treatment failure in patients with mantle cell lymphoma might suggest the presence of cancer stem cells. A small cell population with CD45+/CD19 - was previously reported to represent cancer stem cells. We evaluated the clinical relevance of CD45+/CD19 - cells in bone marrow of patients with mantle cell lymphoma (n = 20). A CD45+/CD19 - cell population was observed in newly diagnosed mantle cell lymphoma, and its percentage correlated with tumor cells in bone marrow (r = 0.832, p = 0.001) and score on the simplified mantle cell lymphoma prognostic index (r = 0.675, p = 0.016). After treatment, CD45+/CD19 - cells decreased (mean: 0.012%), and CD45+/CD19 - cells (0.276%) were higher at relapse or progression than at diagnosis. In conclusion, a CD45+/CD19 - cell population in bone marrow aspirates correlated with the clinical outcome of patients with mantle cell lymphoma.
Collapse
Affiliation(s)
- Sung Min Kim
- a Division of Hematology-Oncology, Department of Medicine , Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , Korea
| | - Seung-Tae Lee
- b Department of Laboratory Medicine and Genetics , Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , Korea.,f Department of Laboratory Medicine , Yonsei University College of Medicine , Seoul , Korea
| | - Kyung Ju Ryu
- c Samsung Biomedical Research Institute, Research Institute for Future Medicine, Samsung Medical Center , Seoul , Korea
| | - Hee-Jin Kim
- b Department of Laboratory Medicine and Genetics , Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , Korea
| | - Sun-Hee Kim
- b Department of Laboratory Medicine and Genetics , Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , Korea
| | - Young Hye Ko
- d Department of Pathology , Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , Korea
| | - Won Seog Kim
- a Division of Hematology-Oncology, Department of Medicine , Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , Korea
| | - Seok Jin Kim
- a Division of Hematology-Oncology, Department of Medicine , Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , Korea.,e Department of Medical Device Management and Research , Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University , Seoul , Korea
| |
Collapse
|
8
|
Ito D, Childress M, Mason N, Winter A, O'Brien T, Henson M, Borgatti A, Lewellen M, Krick E, Stewart J, Lahrman S, Rajwa B, Scott MC, Seelig D, Koopmeiners J, Ruetz S, Modiano J. A double blinded, placebo-controlled pilot study to examine reduction of CD34 +/CD117 +/CD133 + lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphoma. F1000Res 2015; 4:42. [PMID: 28357033 PMCID: PMC5357040 DOI: 10.12688/f1000research.6055.3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 04/13/2017] [Indexed: 01/15/2023] Open
Abstract
We previously described a population of lymphoid progenitor cells (LPCs) in canine B-cell lymphoma defined by retention of the early progenitor markers CD34 and CD117 and “slow proliferation” molecular signatures that persist in the xenotransplantation setting. We examined whether valspodar, a selective inhibitor of the ATP binding cassette B1 transporter (ABCB1, a.k.a., p-glycoprotein/multidrug resistance protein-1) used in the neoadjuvant setting would sensitize LPCs to doxorubicin and extend the length of remission in dogs with therapy naïve large B-cell lymphoma. Twenty dogs were enrolled into a double-blinded, placebo controlled study where experimental and control groups received oral valspodar (7.5 mg/kg) or placebo, respectively, twice daily for five days followed by five treatments with doxorubicin 21 days apart with a reduction in the first dose to mitigate the potential side effects of ABCB1 inhibition. Lymph node and blood LPCs were quantified at diagnosis, on the fourth day of neoadjuvant period, and 1-week after the first chemotherapy dose. Valspodar therapy was well tolerated. There were no differences between groups in total LPCs in lymph nodes or peripheral blood, nor in event-free survival or overall survival. Overall, we conclude that valspodar can be administered safely in the neoadjuvant setting for canine B-cell lymphoma; however, its use to attenuate ABCB1
+ cells does not alter the composition of lymph node or blood LPCs, and it does not appear to be sufficient to prolong doxorubicin-dependent remissions in this setting.
Collapse
Affiliation(s)
- Daisuke Ito
- Animal Cancer Care and Research Program, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA
| | - Michael Childress
- Department of Veterinary Clinical Sciences, Purdue University College of Veterinary Medicine, West Lafayette, IN, 47907, USA
| | - Nicola Mason
- Department of Clinical Studies, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, 19104, USA.,Department of Pathology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, 19104, USA
| | - Amber Winter
- Animal Cancer Care and Research Program, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Clinical Investigation Center, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA
| | - Timothy O'Brien
- Animal Cancer Care and Research Program, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA.,Department of Veterinary Population Medicine, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Stem Cell Institute, University of Minnesota, Minneapolis, MN, 55455, USA
| | - Michael Henson
- Animal Cancer Care and Research Program, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA
| | - Antonella Borgatti
- Animal Cancer Care and Research Program, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA
| | - Mitzi Lewellen
- Animal Cancer Care and Research Program, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA
| | - Erika Krick
- Department of Clinical Studies, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, 19104, USA
| | - Jane Stewart
- Department of Veterinary Clinical Sciences, Purdue University College of Veterinary Medicine, West Lafayette, IN, 47907, USA
| | - Sarah Lahrman
- Department of Veterinary Clinical Sciences, Purdue University College of Veterinary Medicine, West Lafayette, IN, 47907, USA
| | - Bartek Rajwa
- Department of Basic Medical Sciences, Purdue University College of Veterinary Medicine, West Lafayette, IN, 47907, USA
| | - Milcah C Scott
- Animal Cancer Care and Research Program, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA
| | - Davis Seelig
- Animal Cancer Care and Research Program, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA
| | - Joseph Koopmeiners
- Animal Cancer Care and Research Program, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA.,Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, 55455, USA
| | | | - Jaime Modiano
- Animal Cancer Care and Research Program, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA.,Stem Cell Institute, University of Minnesota, Minneapolis, MN, 55455, USA.,Center for Immunology, University of Minnesota, Minneapolis, MN, 55455, USA
| |
Collapse
|
9
|
Ito D, Childress M, Mason N, Winter A, O'Brien T, Henson M, Borgatti A, Lewellen M, Krick E, Stewart J, Lahrman S, Rajwa B, Scott MC, Seelig D, Koopmeiners J, Ruetz S, Modiano J. A double blinded, placebo-controlled pilot study to examine reduction of CD34 +/CD117 +/CD133 + lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphoma. F1000Res 2015; 4:42. [PMID: 28357033 DOI: 10.12688/f1000research.6055.1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 02/09/2015] [Indexed: 01/30/2023] Open
Abstract
We previously described a population of lymphoid progenitor cells (LPCs) in canine B-cell lymphoma defined by retention of the early progenitor markers CD34 and CD117 and "slow proliferation" molecular signatures that persist in the xenotransplantation setting. We examined whether valspodar, a selective inhibitor of the ATP binding cassette B1 transporter (ABCB1, a.k.a., p-glycoprotein/multidrug resistance protein-1) used in the neoadjuvant setting would sensitize LPCs to doxorubicin and extend the length of remission in dogs with therapy naïve large B-cell lymphoma. Twenty dogs were enrolled into a double-blinded, placebo controlled study where experimental and control groups received oral valspodar (7.5 mg/kg) or placebo, respectively, twice daily for five days followed by five treatments with doxorubicin 21 days apart with a reduction in the first dose to mitigate the potential side effects of ABCB1 inhibition. Lymph node and blood LPCs were quantified at diagnosis, on the fourth day of neoadjuvant period, and 1-week after the first chemotherapy dose. Valspodar therapy was well tolerated. There were no differences between groups in total LPCs in lymph nodes or peripheral blood, nor in event-free survival or overall survival. Overall, we conclude that valspodar can be administered safely in the neoadjuvant setting for canine B-cell lymphoma; however, its use to attenuate ABCB1 + cells does not alter the composition of lymph node or blood LPCs, and it does not appear to be sufficient to prolong doxorubicin-dependent remissions in this setting.
Collapse
Affiliation(s)
- Daisuke Ito
- Animal Cancer Care and Research Program, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA
| | - Michael Childress
- Department of Veterinary Clinical Sciences, Purdue University College of Veterinary Medicine, West Lafayette, IN, 47907, USA
| | - Nicola Mason
- Department of Clinical Studies, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, 19104, USA.,Department of Pathology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, 19104, USA
| | - Amber Winter
- Animal Cancer Care and Research Program, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Clinical Investigation Center, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA
| | - Timothy O'Brien
- Animal Cancer Care and Research Program, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA.,Department of Veterinary Population Medicine, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Stem Cell Institute, University of Minnesota, Minneapolis, MN, 55455, USA
| | - Michael Henson
- Animal Cancer Care and Research Program, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA
| | - Antonella Borgatti
- Animal Cancer Care and Research Program, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA
| | - Mitzi Lewellen
- Animal Cancer Care and Research Program, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA
| | - Erika Krick
- Department of Clinical Studies, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, 19104, USA
| | - Jane Stewart
- Department of Veterinary Clinical Sciences, Purdue University College of Veterinary Medicine, West Lafayette, IN, 47907, USA
| | - Sarah Lahrman
- Department of Veterinary Clinical Sciences, Purdue University College of Veterinary Medicine, West Lafayette, IN, 47907, USA
| | - Bartek Rajwa
- Department of Basic Medical Sciences, Purdue University College of Veterinary Medicine, West Lafayette, IN, 47907, USA
| | - Milcah C Scott
- Animal Cancer Care and Research Program, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA
| | - Davis Seelig
- Animal Cancer Care and Research Program, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA
| | - Joseph Koopmeiners
- Animal Cancer Care and Research Program, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA.,Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, 55455, USA
| | | | - Jaime Modiano
- Animal Cancer Care and Research Program, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, 55108, USA.,Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA.,Stem Cell Institute, University of Minnesota, Minneapolis, MN, 55455, USA.,Center for Immunology, University of Minnesota, Minneapolis, MN, 55455, USA
| |
Collapse
|
10
|
Litvinov IV, Netchiporouk E, Cordeiro B, Zargham H, Pehr K, Gilbert M, Zhou Y, Moreau L, Woetmann A, Ødum N, Kupper TS, Sasseville D. Ectopic expression of embryonic stem cell and other developmental genes in cutaneous T-cell lymphoma. Oncoimmunology 2014; 3:e970025. [PMID: 25941598 DOI: 10.4161/21624011.2014.970025] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2014] [Accepted: 09/23/2014] [Indexed: 11/19/2022] Open
Abstract
Cutaneous T-cell lymphoma (CTCL) is a potentially devastating malignancy. The pathogenesis of this cancer remains poorly elucidated. Previous studies focused on analysis of expression and function of known oncogenes and tumor suppressor genes. However, emerging reports highlight that it is also important to analyze the expression of genes that are ectopically expressed in CTCL (e.g., embryonic stem cell genes (ESC), cancer testis (CT) genes, etc.). Currently, it is not known whether ESC genes are expressed in CTCL. In the current work, we analyze by RT-PCR the expression of 26 ESC genes, many of which are known to regulate pluripotency and promote cancer stem cell-like phenotype, in a historic cohort of 60 patients from Boston and in a panel of 11 patient-derived CTCL cell lines and compare such expression to benign inflammatory dermatoses that often clinically mimic CTCL. Our findings document that many critical ESC genes including NANOG, SOX2, OCT4 (POU5F1) and their upstream and downstream signaling members are expressed in CTCL. Similarly, polycomb repressive complex 2 (PRC2) genes (i.e., EZH2, EED, and SUZ12) are also expressed in CTCL lesional skin. Furthermore, select ESC genes (OCT4, EED, TCF3, THAP11, CHD7, TIP60, TRIM28) are preferentially expressed in CTCL samples when compared to benign skin biopsies. Our work suggests that ESC genes are ectopically expressed together with CT genes, thymocyte development genes and B cell-specific genes and may be working in concert to promote tumorigenesis. Specifically, while ESC genes may be promoting cancer stem cell-like phenotype, CT genes may be contributing to aneuploidy and genomic instability by producing aberrant chromosomal translocations. Further analysis of ESC expression and function in this cancer will greatly enhance our fundamental understanding of CTCL and will help us identify novel therapeutic targets.
Collapse
Key Words
- ALCL, Anaplastic Large Cell Lymphoma
- BLK, B-lymphoid kinase
- C-ALCL, Cutaneous Anaplastic Large Cell Lymphoma
- CSC, Cancer Stem Cell
- CTCL, Cutaneous T-Cell Lymphoma
- DMC1, Disrupted Meiotic cDNA 1
- ESC, Embryonic Stem Cell
- EVA1, Epithelial C-like antigen 1
- MF, Mycosis Fungoides
- PBMC, Peripheral Blood Mononucleated Cells
- PLS3, Plastin-3
- PRC1, Polycomb Repressive Complex 1
- PRC2, Polycomb Repressive Complex 2
- SS, Sézary Syndrome
- SYCP1, Synaptonemal Complex Protein 1
- TOX, Thymocyte selection–associated high mobility group box
- ZFX, Zinc finger protein X-linked
- cancer testis genes
- cutaneous T cell lymphoma (CTCL)
- embryonic stem cell genes
- mycosis fungoides (MF)
- polycomb repressive complex 2 (PRC2)
- sézary syndrome (SS)
- thymocyte development genes
Collapse
Affiliation(s)
- Ivan V Litvinov
- Division of Dermatology; McGill University Health Centre ; Montréal, QC Canada
| | - Elena Netchiporouk
- Division of Dermatology; McGill University Health Centre ; Montréal, QC Canada
| | - Brendan Cordeiro
- Division of Dermatology; McGill University Health Centre ; Montréal, QC Canada
| | - Hanieh Zargham
- Division of Dermatology; McGill University Health Centre ; Montréal, QC Canada
| | - Kevin Pehr
- Division of Dermatology; McGill University Health Centre ; Montréal, QC Canada
| | - Martin Gilbert
- Division of Dermatology; Université Laval ; Québec City, QC Canada
| | - Youwen Zhou
- Department of Dermatology and Skin Science; University of British Columbia ; Vancouver, BC Canada
| | - Linda Moreau
- Division of Dermatology; McGill University Health Centre ; Montréal, QC Canada
| | - Anders Woetmann
- Department of International Health, Immunology, and Microbiology; University of Copenhagen ; Copenhagen, Denmark
| | - Niels Ødum
- Department of International Health, Immunology, and Microbiology; University of Copenhagen ; Copenhagen, Denmark
| | - Thomas S Kupper
- Department of Dermatology; Harvard Skin Disease Research Center; Brigham and Women's Hospital; Harvard University ; Boston, MA USA
| | - Denis Sasseville
- Division of Dermatology; McGill University Health Centre ; Montréal, QC Canada
| |
Collapse
|
11
|
Allegra A, Alonci A, Penna G, Innao V, Gerace D, Rotondo F, Musolino C. The cancer stem cell hypothesis: a guide to potential molecular targets. Cancer Invest 2014; 32:470-95. [PMID: 25254602 DOI: 10.3109/07357907.2014.958231] [Citation(s) in RCA: 60] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Common cancer theories hold that tumor is an uncontrolled somatic cell proliferation caused by the progressive addition of random mutations in critical genes that control cell growth. Nevertheless, various contradictions related to the mutation theory have been reported previously. These events may be elucidated by the persistence of residual tumor cells, called Cancer Stem Cells (CSCs) responsible for tumorigenesis, tumor maintenance, tumor spread, and tumor relapse. Herein, we summarize the current understanding of CSCs, with a focus on the possibility to identify specific markers of CSCs, and discuss the clinical application of targeting CSCs for cancer treatment.
Collapse
|
12
|
Medina DJ, Abass-Shereef J, Walton K, Goodell L, Aviv H, Strair RK, Budak-Alpdogan T. Cobblestone-area forming cells derived from patients with mantle cell lymphoma are enriched for CD133+ tumor-initiating cells. PLoS One 2014; 9:e91042. [PMID: 24722054 PMCID: PMC3982953 DOI: 10.1371/journal.pone.0091042] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2013] [Accepted: 02/09/2014] [Indexed: 01/07/2023] Open
Abstract
Mantle cell lymphoma (MCL) is associated with a significant risk of therapeutic failure and disease relapse, but the biological origin of relapse is poorly understood. Here, we prospectively identify subpopulations of primary MCL cells with different biologic and immunophenotypic features. Using a simple culture system, we demonstrate that a subset of primary MCL cells co-cultured with either primary human mesenchymal stromal cells (hMSC) or murine MS-5 cells form in cobblestone-areas consisting of cells with a primitive immunophenotype (CD19−CD133+) containing the chromosomal translocation t (11;14)(q13;q32) characteristic of MCL. Limiting dilution serial transplantation experiments utilizing immunodeficient mice revealed that primary MCL engraftment was only observed when either unsorted or CD19−CD133+ cells were utilized. No engraftment was seen using the CD19+CD133− subpopulation. Our results establish that primary CD19−CD133+ MCL cells are a functionally distinct subpopulation of primary MCL cells enriched for MCL-initiating activity in immunodeficient mice. This rare subpopulation of MCL-initiating cells may play an important role in the pathogenesis of MCL.
Collapse
Affiliation(s)
- Daniel J. Medina
- Department of Medicine, Rutgers - The State University of New Jersey, Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States of America
- * E-mail:
| | - Jeneba Abass-Shereef
- Department of Medicine, Rutgers - The State University of New Jersey, Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States of America
| | - Kelly Walton
- Department of Medicine, Rutgers - The State University of New Jersey, Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States of America
| | - Lauri Goodell
- Department of Pathology, Rutgers - The State University of New Jersey, Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States of America
| | - Hana Aviv
- Department of Pathology, Rutgers - The State University of New Jersey, Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States of America
| | - Roger K. Strair
- Department of Medicine, Rutgers - The State University of New Jersey, Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States of America
| | - Tulin Budak-Alpdogan
- Department of Medicine, Rutgers - The State University of New Jersey, Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States of America
| |
Collapse
|
13
|
Populational equilibrium through exosome-mediated Wnt signaling in tumor progression of diffuse large B-cell lymphoma. Blood 2014; 123:2189-98. [PMID: 24563408 DOI: 10.1182/blood-2013-08-523886] [Citation(s) in RCA: 89] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
Tumors are composed of phenotypically heterogeneous cell populations. The nongenomic mechanisms underlying transitions and interactions between cell populations are largely unknown. Here, we show that diffuse large B-cell lymphomas possess a self-organized infrastructure comprising side population (SP) and non-SP cells, where transitions between clonogenic states are modulated by exosome-mediated Wnt signaling. DNA methylation modulated SP-non-SP transitions and was correlated with the reciprocal expressions of Wnt signaling pathway agonist Wnt3a in SP cells and the antagonist secreted frizzled-related protein 4 in non-SP cells. Lymphoma SP cells exhibited autonomous clonogenicity and exported Wnt3a via exosomes to neighboring cells, thus modulating population equilibrium in the tumor.
Collapse
|